Michael Forbes, CEO of Adastra, claimed in his initial press launch: “Damage reduction is usually a critically significant and mainstream topic, and we have been staying on the forefront of drug regulations over the board.” May well promote substandard and falsified prescription drugs produced or distributed under unregulated and most likely